15:27 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Pfizer's Sutent improves survival without surgery in RCC patients

Data from the Phase III CARMENA trial evaluating Sutent sunitinib from Pfizer Inc. (NYSE:PFE) showed that patients with renal cell carcinoma (RCC) could avoid nephrectomy without compromising survival. The data were presented at the American...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

Gamma-retrovirus gene therapy: Phase I/II data

Researchers at the hospital and colleagues reported data from 3 parallel, open-label, U.S. and European Phase I/II trials in a total of 9 boys with SCID-X1 showing that a single infusion of the gamma-retrovirus gene...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

Mydicar: Phase II started

Celladon said investigators at Assistance Publique-Hopitaux de Paris began the double-blind, placebo-controlled, French Phase II AGENT-HF trial to evaluate a single intracoronary infusion of Mydicar in 44 patients with severe heart failure. Celladon has exclusive...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

IntegraGen, Assistance Publique - Hopitaux de Paris, Centre National de la Recherche Scientifique, Institut National de la Sante et de la Recherche Medicale, Pa

IntegraGen received exclusive, worldwide rights from the hospital, institutes and university for IP covering use of the oncology biomarker hsa-miR-31-3p . The company said expression of the biomarker has shown to be a predictor of...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

Antiretroviral therapy: Phase III data

Researchers at the hospital system and colleagues reported data from the open-label, Cambodian Phase III CAMELIA trial in 661 patients showing that initiating ART 2 weeks after the start of TB treatment significantly improved survival,...
07:00 , Apr 10, 2006 |  BC Week In Review  |  Company News

Ipsogen SAS, INSERM, Institut Gustave Roussy, Assistance Publique - Hopitaux de Paris deal

The institute, hospital and INSERM granted Ipsogen exclusive worldwide rights to use a mutant form of the JAK2 gene to develop diagnostics for myeloproliferative disorders. Financial terms were not disclosed. Ipsogen SAS , Marseille, France...
08:00 , Feb 21, 2005 |  BioCentury  |  Emerging Company Profile

Corporate Profile

BioAlliance Pharma S.A. Paris, France Technology: Drug delivery Disease focus: Candidiasis, HIV, cancer Clinical status: Phase III Founded: 1997 by Dominique Con-stantini, Gilles Avenard University collaborators: CNRS, INSERM, Assistance Publique Hopitaux de Paris, Pasteur Institute,...